A randomised parallel group trial to investigate the effect of Seretide [salmeterol/fluticasone-propionate] withdrawal in COPD [chronic obstructive pulmonary disease] using non-invasive biomarkers and physiological measurements

Trial Profile

A randomised parallel group trial to investigate the effect of Seretide [salmeterol/fluticasone-propionate] withdrawal in COPD [chronic obstructive pulmonary disease] using non-invasive biomarkers and physiological measurements

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2016

At a glance

  • Drugs Salmeterol/fluticasone propionate (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 07 Apr 2011 Actual end date (31 Jul 2007) added as reported by ISRCTN: Current Controlled Trials.
    • 01 Nov 2009 Results published in the European Journal of Clinical Pharmacology.
    • 16 May 2008 Secondary endpoint 'pH' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top